Clinical trial · Observational
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
REAL-WORLD TREATMENT PATTERNS AND CLINICAL EFFECTIVENESS OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR-POSITIVE IN TAIWAN
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work. * have received dacomitinib for their lung cancer. All participants in this study had received dacomitinib. Dacomitinib is a tablet that is taken by mouth at home. They continued to take dacomitnib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Percentage of patients with dacomitinib dosage change and reasons
- timeFrame
- 52 months from index date
- description
- The percentage of patients with dacomitinib dosage change and reason during follow-up period will be summarized.
- measure
- Percentage of patients with dacomitinib treatment discontinuation
- timeFrame
- 52 months from index date
- description
- The percentage of patients with dacomitinib treatment discontinuation for any reason during follow-up period will be summarized.
Secondary outcomes (5)
- measure
- Real-world overall survival (rwOS)
- timeFrame
- 52 months from index date
- description
- Time to death from index date during follow-up period will be summarized by K-M plot with corresponding 95% CI.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Evidence of histologically or cytologically confirmed diagnosis of advanced NSCLC with EGFR-activating mutations detected by an appropriate test * Patients who were treated with dacomitinib as first-line treatment for advanced NSCLC during 01 October 2020 to 31 December 2022. * Age ≥18 years old * Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: * Patients who have been treated with any systemic anti-cancer therapies within 12 months prior to dacomitinib treatment.
References
Publications (0)
Data not yet available